1887

Abstract

The objective of this study was to determine the pharmacodynamic (PD) activity of moxifloxacin against four selected strains (three strains with low MICs and one strain with a high MIC) and two strains (one strain with a low MIC and one strain with a high MIC) in a pharmacokinetic (PK) model in pure cultures as well as in mixed cultures. PK/PD assays of moxifloxacin were carried out with an initial maximum concentration of 4.0 mg l and a half-life of 13 h. The strain with the low MIC was rapidly killed in both pure and mixed cultures in the PK/PD model, while the strain with the high MIC was not killed. None of the strains were rapidly killed in pure or mixed cultures. The bacterial numbers of the strains with low MICs were reduced by about one to two logs after 12 h in pure cultures. The presence of an strain with a low or a high MIC in the mixed culture reduced this effect even further.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45994-0
2005-08-01
2019-11-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/8/JM540808.html?itemId=/content/journal/jmm/10.1099/jmm.0.45994-0&mimeType=html&fmt=ahah

References

  1. Ackermann, G., Schaumann, R., Pless, B., Claros, M. C., Goldstein, E. J. C. & Rodloff, A. C. ( 2000;). Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 19, 228–232.[CrossRef]
    [Google Scholar]
  2. Bauernfeind, A. ( 1997;). Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40, 639–651.[CrossRef]
    [Google Scholar]
  3. Blondeau, J. M., Laskowski, R., Bjarnason, J. & Stewart, C. ( 2000;). Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 14, 45–50.[CrossRef]
    [Google Scholar]
  4. Dalhoff, A., Petersen, U. & Endermann, R. ( 1996;). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410–425.[CrossRef]
    [Google Scholar]
  5. Deutsches Institut für Normung e.V. ( 2000;). Medizinische Mikrobiologie und Immunologie: Diagnostische Verfahren, 3rd edn. Berlin/Wien/Zürich: Beuth.
  6. Edlund, C., Sabouri, S. & Nord, C. E. ( 1998;). Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 17, 193–195.[CrossRef]
    [Google Scholar]
  7. Golan, Y., McDermott, L. A., Jacobus, N. V. & 11 other authors ( 2003;). Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 52, 208–213.[CrossRef]
    [Google Scholar]
  8. Goldstein, E. J. C., Citron, D. M., Hudspeth, M., Hunt Gerardo, S. & Merriam, V. ( 1997;). In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother 41, 1552–1557.
    [Google Scholar]
  9. Gorbach, S. L. ( 1994;). Antibiotic treatment of anaerobic infections. Clin Infect Dis 18 Suppl. 4, S305–S310.
    [Google Scholar]
  10. Hartung, J. ( 1999;). Statistik: Lehr- und Handbuch der angewandten Statistik, 12th edn. München/Wien/Oldenbourg: R. Oldenbourg Verlag.
  11. Hedberg, M. & Nord, C. E. on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria ( 2003;). Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 9, 475–488.[CrossRef]
    [Google Scholar]
  12. Hollander, M. & Wolfe, D. A. ( 1999;). Nonparametric Statistical Methods, 2nd edn. New York: Wiley.
  13. Kleinkauf, N., Ackermann, G., Schaumann, R. & Rodloff, A. C. ( 2001;). Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 45, 1896–1899.[CrossRef]
    [Google Scholar]
  14. Krasemann, C., Meyer, J. & Tillotson, G. ( 2001;). Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 32 Suppl. 1, S51–S63.
    [Google Scholar]
  15. Naber, K. G. & Adam, D. unter Mitwirkung einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e V. ( 1998;). Einteilung der Fluorchinolone. Chemotherapie J 7, 66–68.
    [Google Scholar]
  16. Nagy, E. & Földes, J. ( 1991;). Inactivation of metronidazole by Enterococcus faecalis. J Antimicrob Chemother 27, 63–70.
    [Google Scholar]
  17. Nathens, A. B. & Rotstein, O. D. ( 1996;). Antimicrobial therapy for intraabdominal infection. Am J Surg 172 Suppl. 6A, 1S–6S.
    [Google Scholar]
  18. Olsen, I., Solberg, C. O. & Finegold, S. M. ( 1999;). A primer on anaerobic bacteria and anaerobic infections for the uninitiated. Infection 27, 159–165.[CrossRef]
    [Google Scholar]
  19. Onderdonk, A. B., Bartlett, J. G., Louie, T., Sullivan-Seigler, N. & Gorbach, S. L. ( 1976;). Microbial synergy in experimental intra- abdominal abscess. Infect Immun 13, 22–26.
    [Google Scholar]
  20. Schaumann, R., Ackermann, G., Pless, B., Claros, M. C., Goldstein, E. J. C. & Rodloff, A. C. ( 2000;). In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria. Int J Antimicrob Agents 16, 225–232.[CrossRef]
    [Google Scholar]
  21. Schaumann, R., Blatz, R., Beer, J., Ackermann, G. & Rodloff, A. C. ( 2004;). Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 53, 318–324.[CrossRef]
    [Google Scholar]
  22. Snydman, D. R., Jacobus, N. V., McDermott, L. A. & 10 other authors ( 2002;). In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob Agents Chemother 46, 3276–3279.[CrossRef]
    [Google Scholar]
  23. Stearne, L. E. T., Kooi, C., Goessens, W. H. F., Bakker-Woudenberg, I. A. J. M. & Gyssens, I. C. ( 2001;). In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique. Antimicrob Agents Chemother 45, 243–251.[CrossRef]
    [Google Scholar]
  24. Stearne, L. E. T., Buijk, S. L., Mouton, J. W. & Gyssens, I. C. ( 2002;). Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice. Antimicrob Agents Chemother 46, 3712–3718.[CrossRef]
    [Google Scholar]
  25. Stein, G. E., Schooley, S. & Kaatz, G. W. ( 2003a;). Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high? Clin Infect Dis 37, 1392–1395.[CrossRef]
    [Google Scholar]
  26. Stein, G. E., Schooley, S., Tyrrell, K. L., Citron, D. M. & Goldstein, E. J. C. ( 2003b;). Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 47, 1308–1312.[CrossRef]
    [Google Scholar]
  27. Talan, D. A. ( 2001;). Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32 Suppl. 1, S64–S71.
    [Google Scholar]
  28. Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., Smith, H. & Hoban, D. J. ( 2002;). A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62, 13–59.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45994-0
Loading
/content/journal/jmm/10.1099/jmm.0.45994-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error